Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalization for management of SARS CoV-2 infection~* Positive SARS CoV-2 test~* Age \>=18 years~* Provision of informed consent~* Electrocardiogram (ECG) ≤48 hours prior to enrollment~* Complete blood count, glucose-6 phosphate-dehydrogenase (G6PD), comprehensive metabolic panel and magnesium ≤48 hours prior to enrollment from standard of care.~* If participating in sexual activity that could lead to pregnancy, individuals of reproductive potential who can become pregnant must agree to use contraception throughout the study. At least one of the following must be used throughout the study:~  * Condom (male or female) with or without spermicide~ * Diaphragm or cervical cap with spermicide~ * Intrauterine device (IUD)~ * Hormone-based contraceptive~Exclusion Criteria:~* Contraindication or allergy to chloroquine, hydroxychloroquine or azithromycin~* Current use hydroxychloroquine, chloroquine or azithromycin~* Concurrent use of another investigational agent~* Invasive mechanical ventilation~* Participants who have any severe and/or uncontrolled medical conditions such as:~  * unstable angina pectoris,~ * symptomatic congestive heart failure,~ * myocardial infarction,~ * cardiac arrhythmias or know prolonged QTc \>470 males, \>480 female on ECG~ * pulmonary insufficiency,~ * epilepsy (interaction with chloroquine),~* Prior retinal eye disease~* Concurrent malignancy requiring chemotherapy~* Known Chronic Kidney disease, eGFR\<10 or dialysis~* G-6-PD deficiency, if unknown requires G6PD testing prior to enrollment~  * Known Porphyria~ * Known myasthenia gravis~ * Currently pregnant or planning on getting pregnant while on study~ * Breast feeding~ * AST/ALT \>five times the upper limit of normal ULN\*~ * Bilirubin \>five times the ULN\*~ * Magnesium \<1.4 mEq/L\*~ * Calcium \<8.4mg/dL \>10.6mg/dL\*~ * Potassium \<3.3 \>5.5 mEg/L\*

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine alone (Type: ACTIVE_COMPARATOR): Arm 1: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.
- Hydroxychloroquine plus azithromycin (Type: ACTIVE_COMPARATOR): Arm 2: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.~AND Azithromycin 500mg orally once, followed by 250mg daily for four consecutive days (five days total). The drug will be supplied in 250mg tablets.
- Chloroquine alone (Type: ACTIVE_COMPARATOR): Arm 3: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.
- Chloroquine plus azithromycin (Type: ACTIVE_COMPARATOR): Arm 4: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.~AND Azithromycin 500mg orally once, followed by 250mg daily for 4 consecutive days (5 days total).The drug will be supplied in 250mg tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues